Eliana Merle
Stock Analyst at UBS
(3.91)
# 645
Out of 5,124 analysts
92
Total ratings
53.73%
Success rate
10.69%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eliana Merle
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRNA Moderna | Maintains: Buy | $70 → $40 | $29.49 | +35.64% | 8 | Oct 23, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $72 → $82 | $76.49 | +7.20% | 4 | Sep 12, 2025 | |
| GOSS Gossamer Bio | Upgrades: Buy | $1.25 → $9 | $3.10 | +190.32% | 3 | Sep 10, 2025 | |
| ALT Altimmune | Maintains: Buy | $26 → $24 | $3.61 | +564.82% | 2 | Aug 13, 2025 | |
| RAPT RAPT Therapeutics | Maintains: Neutral | $8 → $9 | $33.87 | -73.43% | 4 | Aug 12, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $458 → $523 | $582.34 | -10.19% | 5 | Aug 12, 2025 | |
| ANAB AnaptysBio | Maintains: Neutral | $18 → $20 | $48.48 | -58.75% | 5 | Aug 12, 2025 | |
| ASND Ascendis Pharma | Maintains: Buy | $306 → $307 | $213.24 | +43.97% | 2 | Aug 8, 2025 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $113 → $114 | $59.43 | +91.82% | 3 | Aug 5, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $403 → $550 | $397.65 | +38.31% | 3 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $45 → $12 | $21.52 | -44.24% | 1 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $8 | $2.24 | +257.14% | 1 | Jul 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 → $5.5 | $4.52 | +21.68% | 3 | Jun 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $74 → $21 | $11.86 | +77.07% | 6 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $70 | $77.81 | -10.04% | 3 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $44 | $25.12 | +75.16% | 8 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5 → $2.2 | $1.35 | +63.57% | 4 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $71 | $79.65 | -10.86% | 2 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $26.29 | +6.50% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $5.92 | +102.70% | 1 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $3 | $4.65 | -35.48% | 1 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $97 → $131 | $95.20 | +37.61% | 6 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3 → $5 | $27.96 | -82.12% | 3 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $18 | $40.40 | -55.45% | 2 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $45 → $42 | $23.93 | +75.51% | 4 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $15.68 | +40.31% | 1 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $47 | $14.41 | +226.16% | 1 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $14.24 | +12.36% | 2 | May 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $192 → $134 | $32.68 | +310.04% | 3 | Aug 19, 2020 |
Moderna
Oct 23, 2025
Maintains: Buy
Price Target: $70 → $40
Current: $29.49
Upside: +35.64%
BridgeBio Pharma
Sep 12, 2025
Maintains: Buy
Price Target: $72 → $82
Current: $76.49
Upside: +7.20%
Gossamer Bio
Sep 10, 2025
Upgrades: Buy
Price Target: $1.25 → $9
Current: $3.10
Upside: +190.32%
Altimmune
Aug 13, 2025
Maintains: Buy
Price Target: $26 → $24
Current: $3.61
Upside: +564.82%
RAPT Therapeutics
Aug 12, 2025
Maintains: Neutral
Price Target: $8 → $9
Current: $33.87
Upside: -73.43%
Madrigal Pharmaceuticals
Aug 12, 2025
Maintains: Buy
Price Target: $458 → $523
Current: $582.34
Upside: -10.19%
AnaptysBio
Aug 12, 2025
Maintains: Neutral
Price Target: $18 → $20
Current: $48.48
Upside: -58.75%
Ascendis Pharma
Aug 8, 2025
Maintains: Buy
Price Target: $306 → $307
Current: $213.24
Upside: +43.97%
BioMarin Pharmaceutical
Aug 5, 2025
Maintains: Buy
Price Target: $113 → $114
Current: $59.43
Upside: +91.82%
Alnylam Pharmaceuticals
Aug 1, 2025
Maintains: Buy
Price Target: $403 → $550
Current: $397.65
Upside: +38.31%
Jul 21, 2025
Downgrades: Neutral
Price Target: $45 → $12
Current: $21.52
Upside: -44.24%
Jul 15, 2025
Maintains: Buy
Price Target: $4 → $8
Current: $2.24
Upside: +257.14%
Jun 26, 2025
Downgrades: Neutral
Price Target: $12 → $5.5
Current: $4.52
Upside: +21.68%
May 15, 2025
Maintains: Buy
Price Target: $74 → $21
Current: $11.86
Upside: +77.07%
May 13, 2025
Maintains: Buy
Price Target: $72 → $70
Current: $77.81
Upside: -10.04%
Apr 29, 2025
Initiates: Overweight
Price Target: $44
Current: $25.12
Upside: +75.16%
Jan 28, 2025
Maintains: Neutral
Price Target: $5 → $2.2
Current: $1.35
Upside: +63.57%
Jan 8, 2025
Maintains: Buy
Price Target: $65 → $71
Current: $79.65
Upside: -10.86%
Jan 7, 2025
Initiates: Buy
Price Target: $28
Current: $26.29
Upside: +6.50%
Nov 12, 2024
Initiates: Buy
Price Target: $12
Current: $5.92
Upside: +102.70%
Nov 12, 2024
Initiates: Neutral
Price Target: $3
Current: $4.65
Upside: -35.48%
Sep 18, 2024
Maintains: Neutral
Price Target: $97 → $131
Current: $95.20
Upside: +37.61%
Apr 4, 2024
Maintains: Neutral
Price Target: $3 → $5
Current: $27.96
Upside: -82.12%
Mar 27, 2024
Maintains: Buy
Price Target: $19 → $18
Current: $40.40
Upside: -55.45%
May 19, 2023
Maintains: Buy
Price Target: $45 → $42
Current: $23.93
Upside: +75.51%
Oct 13, 2022
Initiates: Buy
Price Target: $22
Current: $15.68
Upside: +40.31%
Jun 23, 2022
Maintains: Buy
Price Target: $51 → $47
Current: $14.41
Upside: +226.16%
May 21, 2021
Initiates: Buy
Price Target: $16
Current: $14.24
Upside: +12.36%
Aug 19, 2020
Maintains: Neutral
Price Target: $192 → $134
Current: $32.68
Upside: +310.04%